Grupo Supervielle (SUPV) Projected to Post Quarterly Earnings on Wednesday

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.

Grupo Supervielle SA (SUPV) reported Q2 2026 earnings, highlighting a return to profitability. Loan demand declined, and net fee income is expected to fall 5%-8%. NIM guidance was lowered to 17%-19%, and ROE is projected at 2%-4% for 2026. Management expects cost savings to reflect in metrics from Q3, with loan growth guidance reduced to 10%-15%. IOL's net income decreased due to lower trading activity but saw growing assets under custody.

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV) reported 2Q26 results for the period ended June 30, 2026. It returned to profitability with attributable net income of AR$12.8bn and ROAE of 4.4%, or structural net income AR$41.9bn and structural ROAE 14.4% excluding extraordinary severance. NPL ratio fell to 5.5% and net cost of risk to 5.6%.

Grupo Supervielle S.A. (SUPV) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ ​ ​ ​ GRUPO SUPERVIELLE S.A. TABLE OF CONTENTS ​ ​ ​Item ​ ​ ​1. Grupo Supervielle S.A. – 2Q26 Earnings Report ​ ​ ​ ​ ​ Content Financial highlights & Key ratios ‌ 9 Review of consolidated results ‌ 13 Profitability & Comprehensive Income ‌ 13 Net financial income ‌ 1

S&P upgraded Argentina’s sovereign credit rating from CCC+ to B- on Thursday, citing reduced economic vulnerability and improved external liquidity and debt-servicing capacity, including reserve accumulation and fiscal balance. Argentina’s country-risk index fell to 444 bps (below 450). Dollar bonds rose up to 3.3% and the S&P Merval gained 5.68% (7.3% in hard currency); ADRs climbed as much as 11.5%.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.